Better Recovery Story Buy: Pfizer vs Moderna
A few years ago, both (NYSE: PFE) and Moderna (NASDAQ: MRNA) were flying high: from an earnings and share performance perspective. They each sold a leading coronavirus vaccine -- and Pfizer sold a COVID treatment too -- and these products generated billions of dollars in earnings for the companies.
Pfizer and Moderna still sell these top products, but demand for them has declined as we head toward a post-pandemic world. That's weighed on earnings, pushed the companies to cut costs to match infrastructure to demand, and hurt share price performance in recent times. Pfizer and Moderna shares each have lost about 30% over the past year.
But the tide may be about to turn for these struggling stocks, thanks to each company's focus on long-term growth. That makes them both compelling buys today. But if you could only get in on one of these recovery stories right now, which one should you go for? Let's find out.
Source Fool.com
Pfizer Inc. Stock
The stock is one of the favorites of our community with 29 Buy predictions and 4 Sell predictions.
As a result the target price of 40 € shows a very positive potential of 50.38% compared to the current price of 26.6 € for Pfizer Inc..
